Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.52 |
| ▸ | SLC28A1 | O00337 | 3/20 | 0.52 |
| ▸ | GMPS | P49915 | 1/20 | 0.49 |
| ▸ | PI4KA | P42356 | 3/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.46 |
| ▸ | AHCY | P23526 | 4/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.44 |
| ▸ | GAPDH | P04406 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | STAT6 | P42226 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8590840 | 1.00 | ADORA3 (0.52) | ADORA3ADORA2ASLC28A1GMPSPI4KA | |
| SCHEMBL5607133 | 0.84 | ADORA2A (0.36) | ADORA3ADORA2ASLC28A1GMPSAHCY | |
| SCHEMBL15741480 | 0.83 | AHCY (0.47) | ADORA3ADORA2ASLC28A1AHCYADORA2B | |
| SCHEMBL27214952 | 0.80 | AHCY (0.35) | ADORA3ADORA2ASLC28A1AHCYADORA1 | |
| SCHEMBL1934830 | 0.79 | ADORA2A (0.51) | ADORA3ADORA2ASLC28A1GMPSPI4KA | |
| SCHEMBL10785491 | 0.78 | ADORA3 (0.31) | ADORA3ADORA2ASLC28A1 | |
| SCHEMBL23025515 | 0.78 | ADORA3 (0.53) | ADORA3ADORA2ASLC28A1GMPSPI4KA | |
| SCHEMBL25521510 | 0.78 | ADORA3 (0.53) | ADORA3ADORA2ASLC28A1GMPSPI4KA | |
| SCHEMBL9667894 | 0.77 | ADORA3 (0.46) | ADORA3MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9450389 | 0.76 | HSP90AA1 (0.36) | ADORA3ADORA2ASLC28A1AHCYADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1992010198-A1 | IMMUNOTHERAPEUTIC AGENTS, COMPOSITIONS AND METHODS | JOHNSON & JOHNSON RESEARCH PTY LIMITED (AU) | 1992-06-25 | — | — | WO | claimed |
| EP-0121635-A1 | 3',5',-Diarabinosides, their preparation and their therapeutical application | SYNTHELABO (FR) | 1984-10-17 | — | — | EP | claimed |
| EP-2509990-A1 | NOVEL PHOSPH(ON)ATE- AND SULF(ON)ATE-BASED PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-10-17 | — | — | EP | disclosed |
| US-20120245029-A1 | NOVEL PHOSPH(ON)ATE- AND SULF(ON)ATE-BASED PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-09-27 | — | — | US | disclosed |
| WO-2011069688-A1 | NOVEL PHOSPH(ON)ATE- AND SULF(ON)ATE-BASED PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2011-06-16 | — | — | WO | disclosed |
| EP-0891374-A4 | UNIQUE ASSOCIATED KAPOSI'S SARCOMA VIRUS SEQUENCES AND USES THEREOF | UNIV COLUMBIA (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0891374-A1 | UNIQUE ASSOCIATED KAPOSI'S SARCOMA VIRUS SEQUENCES AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997027208-A1 | UNIQUE ASSOCIATED KAPOSI'S SARCOMA VIRUS SEQUENCES AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1997-07-31 | — | — | WO | disclosed |
| EP-0674529-A1 | LIPID PRODRUGS FOR ORAL ADMINISTRATION | NeXstar Pharmaceuticals, Inc. (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994013324-A1 | LIPID PRODRUGS FOR ORAL ADMINISTRATION | VESTAR, INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| EP-0517859-A1 | OLIGONUCLEOTIDE THERAPIES FOR MODULATING THE EFFECTS OF HERPESVIRUSES | ISIS PHARMACEUTICALS, INC. (US) | 1992-12-16 | — | — | EP | disclosed |
| WO-1991012811-A1 | OLIGONUCLEOTIDE THERAPIES FOR MODULATING THE EFFECTS OF HERPESVIRUSES | ISIS PHARMACEUTICALS, INC. (US) | 1991-09-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245029-A1 | NOVEL PHOSPH(ON)ATE- AND SULF(ON)ATE-BASED PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | TYMP, PNP, MTAP | ADORA3 100/4885ADORA2A 191/4885SLC28A1 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.